Pooja M. Varman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Pooja M. Varman has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
Zahraa Al-Hilli
Breast Center, Integrated Surgical Institute, Cleveland Clinic, Cleveland, USA
6 shared publicationsRahul Rangan
Breast Center, Integrated Surgical Institute, Cleveland Clinic, Cleveland, USA
4 shared publicationsVincent Wu
Breast Center, Integrated Surgical Institute, Cleveland Clinic, Cleveland, OH, USA
4 shared publicationsAndrew Conner
Cleveland Clinic, Digestive Diseases Institute, Cleveland, USA
3 shared publicationsAmanda Cech
Department of General Surgery, Digestive Diseases and Surgery Institute, Cleveland Clinic, Cleveland, USA
2 shared publicationsAmanda Maggiotto
Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA
2 shared publications
Latest Publications
- 1 August 2026
- Published by Journal of Graduate Medical Education in Journal of Graduate Medical Education
- Vol. 18 (4) , 448-457
Where Are We and Where Are We Going? A GME Program Scorecard for Continuous Programmatic Improvement
Background: Graduate medical education (GME) leaders face challenges in evaluating program performance due to fragmented data systems and limited resources. Dashboards have been proposed, but few are scalable, participant-informed, and feasible without new infrastructure. Objective: To develop and implement a centralized, participant-informed GME Program Scorecard (GPS) that enables continuous program evaluation and improvement using existing data systems without new data entry. Methods: The GPS was developed at a large academic medical center in 2022-2023. A consensus development panel of 20 GME administrators identified 42 candidate metrics across 13 systems. Program directors (PDs) from the largest residency programs were surveyed (11; 9 responses, 81.8%) to rate each metric’s value. The 17 most supported metrics were integrated into a Tableau-based dashboard. The GPS was piloted with 4 programs (3 Accreditation Council for Graduate Medical Education [ACGME]-accredited, 1 non-ACGME-accredited), involving 8 PDs and program coordinators. Feedback was collected via structured forms and a focus group. Metrics were rated on a 1 to 5 scale, with lower scores indicating higher priority. Results: Pre-intervention survey results guided prioritization, with 92.9% of metrics receiving a mean score <3. Pilot users reported high acceptability and identified design refinements incorporated before institutional launch. Development required 2920 analyst hours and $1,600 in licenses. Since launching in January 2024, 309 users (61.4% of 503 potential users) have accessed the GPS with 3933 total views. Conclusions: The GPS demonstrated feasibility, requiring 2920 analyst hours and $1,600 in licenses, and with 61.4% of potential users accessing the dashboard within 22 months of launch.
- 1 August 2026
- Published by Journal of Graduate Medical Education in Journal of Graduate Medical Education
- Vol. 18 (4) , 448-457
Where Are We and Where Are We Going? A GME Program Scorecard for Continuous Programmatic Improvement
Background: Graduate medical education (GME) leaders face challenges in evaluating program performance due to fragmented data systems and limited resources. Dashboards have been proposed, but few are scalable, participant-informed, and feasible without new infrastructure. Objective: To develop and implement a centralized, participant-informed GME Program Scorecard (GPS) that enables continuous program evaluation and improvement using existing data systems without new data entry. Methods: The GPS was developed at a large academic medical center in 2022-2023. A consensus development panel of 20 GME administrators identified 42 candidate metrics across 13 systems. Program directors (PDs) from the largest residency programs were surveyed (11; 9 responses, 81.8%) to rate each metric’s value. The 17 most supported metrics were integrated into a Tableau-based dashboard. The GPS was piloted with 4 programs (3 Accreditation Council for Graduate Medical Education [ACGME]-accredited, 1 non-ACGME-accredited), involving 8 PDs and program coordinators. Feedback was collected via structured forms and a focus group. Metrics were rated on a 1 to 5 scale, with lower scores indicating higher priority. Results: Pre-intervention survey results guided prioritization, with 92.9% of metrics receiving a mean score <3. Pilot users reported high acceptability and identified design refinements incorporated before institutional launch. Development required 2920 analyst hours and $1,600 in licenses. Since launching in January 2024, 309 users (61.4% of 503 potential users) have accessed the GPS with 3933 total views. Conclusions: The GPS demonstrated feasibility, requiring 2920 analyst hours and $1,600 in licenses, and with 61.4% of potential users accessing the dashboard within 22 months of launch.
- Open Access
- 20 July 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (11) , 9728-9729
ASO Author Reflections: Rethinking Clinical Nodal Staging in Breast Cancer
- 20 July 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (11) , 9728-9729
Open AccessASO Author Reflections: Rethinking Clinical Nodal Staging in Breast Cancer
- Open Access
- 16 July 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (11) , 9719-9727
Is It Time to Redefine Clinical Nodal Staging for Breast Cancer?
Background: The current American Joint Committee on Cancer (AJCC) staging system defines cN1 by node mobility rather than number, while pathologic staging stratifies by node count. Whether cN1 patients with four or more suspicious nodes on pretreatment imaging differ in pathologic stage and survival outcomes from those with fewer nodes is unclear. Patients and Methods: Patients with biopsy-proven cN1 or cN2a breast cancer diagnosed in 2018–2023 who received neoadjuvant chemotherapy (NAC) at a single institution were identified. Pretreatment imaging was reviewed and cases categorized as cN1a (1–3 mobile nodes), cN1b (≥ 4 mobile nodes), or cN2a (matted nodes). Clinicopathologic characteristics were compared using χ 2 and Kruskal–Wallis tests. DFS and OS were estimated with Kaplan–Meier curves and multivariable Cox regression. Results: Among 618 cases, 390 (63.1%) were cN1a, 166 (26.9%) cN1b, and 62 (10.0%) cN2a. Pathologic complete response (pCR) rates did not differ across groups (29.5%, 28.9%, 35.5%; P = 0.598). Among patients with residual nodal disease, mean positive nodes were 2.8, 4.6, and 5.5 in cN1a, cN1b, and cN2a ( P < 0.001), respectively. Pathologic nodal stage was ypN2 or higher in 12.8%, 24.1%, and 29.0% ( P = 0.001), and cN1b was independently associated with upstaging on multivariable analysis (OR 1.958, 95% CI 1.184–3.237, P = 0.009). At median follow-up of 41.4 months, 3-year DFS (88.0%, 89.0%, 80.6%; P = 0.949) and OS (91.6%, 92.3%, 91.6%; P = 0.947) did not differ across groups. Conclusions: In cN1 breast cancer, imaging-defined nodal burden ≥ 4 nodes independently predicts upstaging and greater residual nodal burden after NAC, aligning pathologically with cN2a disease. Imaging-based subcategorization of cN1 disease may have implications for staging, surgical planning, and trial eligibility.
- 16 July 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (11) , 9719-9727
Open AccessIs It Time to Redefine Clinical Nodal Staging for Breast Cancer?
Background: The current American Joint Committee on Cancer (AJCC) staging system defines cN1 by node mobility rather than number, while pathologic staging stratifies by node count. Whether cN1 patients with four or more suspicious nodes on pretreatment imaging differ in pathologic stage and survival outcomes from those with fewer nodes is unclear. Patients and Methods: Patients with biopsy-proven cN1 or cN2a breast cancer diagnosed in 2018–2023 who received neoadjuvant chemotherapy (NAC) at a single institution were identified. Pretreatment imaging was reviewed and cases categorized as cN1a (1–3 mobile nodes), cN1b (≥ 4 mobile nodes), or cN2a (matted nodes). Clinicopathologic characteristics were compared using χ 2 and Kruskal–Wallis tests. DFS and OS were estimated with Kaplan–Meier curves and multivariable Cox regression. Results: Among 618 cases, 390 (63.1%) were cN1a, 166 (26.9%) cN1b, and 62 (10.0%) cN2a. Pathologic complete response (pCR) rates did not differ across groups (29.5%, 28.9%, 35.5%; P = 0.598). Among patients with residual nodal disease, mean positive nodes were 2.8, 4.6, and 5.5 in cN1a, cN1b, and cN2a ( P < 0.001), respectively. Pathologic nodal stage was ypN2 or higher in 12.8%, 24.1%, and 29.0% ( P = 0.001), and cN1b was independently associated with upstaging on multivariable analysis (OR 1.958, 95% CI 1.184–3.237, P = 0.009). At median follow-up of 41.4 months, 3-year DFS (88.0%, 89.0%, 80.6%; P = 0.949) and OS (91.6%, 92.3%, 91.6%; P = 0.947) did not differ across groups. Conclusions: In cN1 breast cancer, imaging-defined nodal burden ≥ 4 nodes independently predicts upstaging and greater residual nodal burden after NAC, aligning pathologically with cN2a disease. Imaging-based subcategorization of cN1 disease may have implications for staging, surgical planning, and trial eligibility.
- 15 July 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (11) , 9641
ASO Visual Abstract: Targeted Multidisciplinary Continuous Improvement Process Reduces Time to Breast Cancer Surgery with Immediate Reconstruction
- 15 July 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (11) , 9641
ASO Visual Abstract: Targeted Multidisciplinary Continuous Improvement Process Reduces Time to Breast Cancer Surgery with Immediate Reconstruction
- Open Access
- 14 July 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (11) , 9633-9640
Targeted Multidisciplinary Continuous Improvement Process Reduces Time to Breast Cancer Surgery with Immediate Reconstruction
Background: Breast surgery with immediate breast reconstruction (IBR) is associated with delays in definitive surgery and adjuvant therapy. We evaluated a multiphase quality improvement (QI) initiative to reduce time to treatment (TTT) for patients undergoing upfront surgery with IBR. Methods: This retrospective cohort study included patients with newly diagnosed breast cancer undergoing upfront surgery at a single institution between January 2022 and June 2025. Patients with metastatic disease, neoadjuvant therapy, or first treatment outside this institution were excluded. The QI initiative comprised three phases: (1) weekly multidisciplinary team huddle; (2) standardized communication protocol; and (3) OR alignment between breast and plastic surgery. Primary outcome was median TTT. Time to treatment for non-IBR patients was tracked concurrently as a balancing metric. Results: A total of 3,324 patients met inclusion criteria; 1,100 (33.1%) underwent surgery with IBR and 2,224 (66.9%) without. The cohort was predominantly early-stage (82.8% cTis/T1). Median TTT declined from 56 to 36 days in the IBR group and from 41 to 29 days in the non-IBR group (both P < 0.001). The proportion waiting longer than 45 days declined from 67.4 to 27.3% for IBR and from 40.5 to 22.9% for non-IBR (both P < 0.001). Only the IBR group demonstrated statistically significant improvement through Phase 3 ( P < 0.001), while the non-IBR group plateaued after Phase 2. Conclusions: A targeted multidisciplinary QI initiative meaningfully reduced TTT for breast cancer patients undergoing upfront surgery with IBR without delaying non-IBR patients. Operating room (OR) alignment was the pivotal intervention, highlighting the importance of system-level coordination between breast and plastic surgery.
- 14 July 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (11) , 9633-9640
Open AccessTargeted Multidisciplinary Continuous Improvement Process Reduces Time to Breast Cancer Surgery with Immediate Reconstruction
Background: Breast surgery with immediate breast reconstruction (IBR) is associated with delays in definitive surgery and adjuvant therapy. We evaluated a multiphase quality improvement (QI) initiative to reduce time to treatment (TTT) for patients undergoing upfront surgery with IBR. Methods: This retrospective cohort study included patients with newly diagnosed breast cancer undergoing upfront surgery at a single institution between January 2022 and June 2025. Patients with metastatic disease, neoadjuvant therapy, or first treatment outside this institution were excluded. The QI initiative comprised three phases: (1) weekly multidisciplinary team huddle; (2) standardized communication protocol; and (3) OR alignment between breast and plastic surgery. Primary outcome was median TTT. Time to treatment for non-IBR patients was tracked concurrently as a balancing metric. Results: A total of 3,324 patients met inclusion criteria; 1,100 (33.1%) underwent surgery with IBR and 2,224 (66.9%) without. The cohort was predominantly early-stage (82.8% cTis/T1). Median TTT declined from 56 to 36 days in the IBR group and from 41 to 29 days in the non-IBR group (both P < 0.001). The proportion waiting longer than 45 days declined from 67.4 to 27.3% for IBR and from 40.5 to 22.9% for non-IBR (both P < 0.001). Only the IBR group demonstrated statistically significant improvement through Phase 3 ( P < 0.001), while the non-IBR group plateaued after Phase 2. Conclusions: A targeted multidisciplinary QI initiative meaningfully reduced TTT for breast cancer patients undergoing upfront surgery with IBR without delaying non-IBR patients. Operating room (OR) alignment was the pivotal intervention, highlighting the importance of system-level coordination between breast and plastic surgery.
- 14 July 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (11) , 9730
ASO Visual Abstract: Is It Time to Redefine Clinical Nodal Staging for Breast Cancer?
- 14 July 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (11) , 9730
ASO Visual Abstract: Is It Time to Redefine Clinical Nodal Staging for Breast Cancer?
- Open Access
- 7 October 2025
- Published by Elsevier in Journal of Surgical Education
- Vol. 82 (12) , 103714
Preference Signaling in General Surgery: A Qualitative Study of Program Director Perspectives
- 7 October 2025
- Published by Elsevier in Journal of Surgical Education
- Vol. 82 (12) , 103714
Open AccessPreference Signaling in General Surgery: A Qualitative Study of Program Director Perspectives
- Open Access
- 30 August 2025
- Published by Elsevier in Journal of Surgical Education
- Vol. 82 (12) , 103655
Feasibility of Using AI to Evaluate General Surgery Residency Application Personal Statements
- 30 August 2025
- Published by Elsevier in Journal of Surgical Education
- Vol. 82 (12) , 103655
Open AccessFeasibility of Using AI to Evaluate General Surgery Residency Application Personal Statements
- 27 August 2025
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 32 (11) , 8297-8298
ASO Visual Abstract: Impact of Second Opinions on Time to Treatment of Breast Cancer
- 27 August 2025
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 32 (11) , 8297-8298
ASO Visual Abstract: Impact of Second Opinions on Time to Treatment of Breast Cancer